Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geizler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H; Clinical Proteomic Tumor Analysis Consortium.

Cell. 2019 Oct 31;179(4):964-983.e31. doi: 10.1016/j.cell.2019.10.007.

2.

RAB38 is a potential prognostic factor for tumor recurrence in non-small cell lung cancer.

Hsieh JJ, Hou MM, Chang JW, Shen YC, Cheng HY, Hsu T.

Oncol Lett. 2019 Sep;18(3):2598-2604. doi: 10.3892/ol.2019.10547. Epub 2019 Jun 28.

3.

Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.

Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA.

Clin Genitourin Cancer. 2019 Oct;17(5):373-379.e4. doi: 10.1016/j.clgc.2019.06.011. Epub 2019 Jun 26.

PMID:
31326335
4.

A direct comparison of mouse and human intestinal development using epithelial gene expression patterns.

Stanford AH, Gong H, Noonan M, Lewis AN, Gong Q, Lanik WE, Hsieh JJ, Lueschow SR, Frey MR, Good M, McElroy SJ.

Pediatr Res. 2019 Jun 26. doi: 10.1038/s41390-019-0472-y. [Epub ahead of print]

PMID:
31242501
5.

Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.

Gatto F, Blum KA, Hosseini SS, Ghanaat M, Kashan M, Maccari F, Galeotti F, Hsieh JJ, Volpi N, Hakimi AA, Nielsen J.

Eur Urol Oncol. 2018 Oct;1(5):364-377. doi: 10.1016/j.euo.2018.04.015. Epub 2018 Jun 13.

6.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

7.

Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.

Poehlman WL, Hsieh JJ, Feltus FA.

Sci Rep. 2019 Feb 27;9(1):2899. doi: 10.1038/s41598-019-39875-y.

8.

Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics.

Silk MT, Mikkilineni N, Silk TC, Zabor EC, Ostrovnaya I, Hakimi AA, Hsieh JJ, Ziv E, Rekhtman N, Solomon SB, Durack JC.

Anal Cell Pathol (Amst). 2018 Dec 10;2018:2898962. doi: 10.1155/2018/2898962. eCollection 2018.

9.

Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models.

Dong Y, Eskandari R, Ray C, Granlund KL, Santos-Cunha LD, Miloushev VZ, Tee SS, Jeong S, Aras O, Chen YB, Cheng EH, Hsieh JJ, Keshari KR.

Cancer Res. 2019 Jan 1;79(1):242-250. doi: 10.1158/0008-5472.CAN-18-2231. Epub 2018 Nov 20.

PMID:
30459151
10.

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.

Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ.

Lancet Oncol. 2018 Dec;19(12):1688-1698. doi: 10.1016/S1470-2045(18)30648-X. Epub 2018 Nov 8.

11.

Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.

Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH.

J Clin Oncol. 2018 Oct 29:JCO2018792549. doi: 10.1200/JCO.2018.79.2549. [Epub ahead of print]

PMID:
30372397
12.

BH3-Dependent and Independent Activation of BAX and BAK in Mitochondrial Apoptosis.

Jeng PS, Inoue-Yamauchi A, Hsieh JJ, Cheng EH.

Curr Opin Physiol. 2018 Jun;3:71-81. doi: 10.1016/j.cophys.2018.03.005. Epub 2018 Mar 20.

13.

PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.

Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ.

Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16.

PMID:
30327302
14.

Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.

Qu L, Wang ZL, Chen Q, Li YM, He HW, Hsieh JJ, Xue S, Wu ZJ, Liu B, Tang H, Xu XF, Xu F, Wang J, Bao Y, Wang AB, Wang D, Yi XM, Zhou ZK, Shi CJ, Zhong K, Sheng ZC, Zhou YL, Jiang J, Chu XY, He J, Ge JP, Zhang ZY, Zhou WQ, Chen C, Yang JH, Sun YH, Wang LH.

Eur Urol. 2018 Dec;74(6):756-763. doi: 10.1016/j.eururo.2018.07.032. Epub 2018 Aug 22.

PMID:
30143382
15.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

16.

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh JJ, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S.

Oncogene. 2018 Aug;37(34):4692-4710. doi: 10.1038/s41388-018-0273-5. Epub 2018 May 14.

17.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

18.

Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro.

Wu YC, Shen YC, Chang JW, Hsieh JJ, Chu Y, Wang CH.

Cytokine. 2018 Oct;110:94-103. doi: 10.1016/j.cyto.2018.04.027. Epub 2018 Apr 26.

PMID:
29705397
19.

Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O'Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, Hazell S, Eichler-Jonsson C, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Jabbar F, Spain L, Lall S, Guarch R, Falzon M, Proctor I, Pickering L, Gore M, Watkins TBK, Ward S, Stewart A, DiNatale R, Becerra MF, Reznik E, Hsieh JJ, Richmond TA, Mayhew GF, Hill SM, McNally CD, Jones C, Rosenbaum H, Stanislaw S, Burgess DL, Alexander NR, Swanton C; PEACE; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):581-594.e12. doi: 10.1016/j.cell.2018.03.057. Epub 2018 Apr 12.

20.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

21.

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.

Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS.

Radiology. 2018 May;287(2):667-675. doi: 10.1148/radiol.2017162610. Epub 2018 Jan 31.

22.

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.

Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ.

J Pathol. 2018 Apr;244(5):525-537. doi: 10.1002/path.5022. Epub 2018 Feb 14. Review.

PMID:
29266437
23.

ΔNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival.

Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, Ganesan YT, Han S, Liu H, Hsieh JJ, Cheng EH.

Cell Rep. 2017 Dec 5;21(10):2926-2939. doi: 10.1016/j.celrep.2017.11.030.

24.

Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.

Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman J, Hsieh JJ, Hakimi AA.

Urol Oncol. 2019 Jan;37(1):12-17. doi: 10.1016/j.urolonc.2017.10.012. Epub 2017 Nov 11.

PMID:
29132830
25.

Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.

Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ.

Eur Urol Focus. 2018 Dec;4(6):986-994. doi: 10.1016/j.euf.2017.09.016. Epub 2017 Oct 20.

26.

Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?

Casuscelli J, Hsieh JJ.

Eur Urol. 2018 Jan;73(1):69-70. doi: 10.1016/j.eururo.2017.09.026. Epub 2017 Oct 12. No abstract available.

PMID:
29032154
27.

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL.

Blood. 2017 Dec 14;130(24):2631-2641. doi: 10.1182/blood-2017-03-775569. Epub 2017 Oct 10.

28.

Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2019 Jul;5(4):642-649. doi: 10.1016/j.euf.2017.09.008. Epub 2017 Sep 24.

PMID:
28951115
29.

SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer.

Nargund AM, Osmanbeyoglu HU, Cheng EH, Hsieh JJ.

Mol Cell Oncol. 2017 Jun 19;4(4):e1342747. doi: 10.1080/23723556.2017.1342747. eCollection 2017.

30.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

31.

Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.

Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ.

Eur Urol Focus. 2017 Dec;3(6):590-598. doi: 10.1016/j.euf.2016.08.005. Epub 2016 Aug 25.

32.

Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.

Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2017 Oct;3(4-5):421-427. doi: 10.1016/j.euf.2016.06.015. Epub 2016 Jul 16.

33.

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.

Carlo MI, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A, Arcila M, Ladanyi M, Lee W, Chen YB, Lee CH, Feldman DR, Hakimi AA, Motzer RJ, Hsieh JJ, Voss MH.

Kidney Cancer. 2017 Jul 26;1(1):49-56. doi: 10.3233/KCA-160003.

34.

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice.

Casuscelli J, Vano YA, Fridman WH, Hsieh JJ.

Kidney Cancer. 2017 Jul 26;1(1):3-13. doi: 10.3233/KCA-170008. Review.

35.

Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients.

Rosenzweig B, Rubinstein ND, Reznik E, Shingarev R, Juluru K, Akin O, Hsieh JJ, Jaimes EA, Russo P, Susztak K, Coleman JA, Hakimi AA.

PLoS One. 2017 Jul 20;12(7):e0180350. doi: 10.1371/journal.pone.0180350. eCollection 2017.

36.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
37.

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.

Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH.

Nat Commun. 2017 Jul 17;8:16078. doi: 10.1038/ncomms16078.

38.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ.

JCI Insight. 2017 Jun 15;2(12). pii: 92688. doi: 10.1172/jci.insight.92688. eCollection 2017 Jun 15.

39.

Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.

Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH.

Clin Genitourin Cancer. 2017 Dec;15(6):e987-e994. doi: 10.1016/j.clgc.2017.04.012. Epub 2017 Apr 26.

40.

Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.

Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA.

Nat Commun. 2017 May 10;8:15165. doi: 10.1038/ncomms15165.

41.

Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.

Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.

Urol Oncol. 2017 Aug;35(8):532.e7-532.e13. doi: 10.1016/j.urolonc.2017.03.015. Epub 2017 Apr 10.

42.

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, Lekaye CL, Koutcher JA, Leslie CS, Creighton CJ, Weinhold N, Lee W, Tickoo SK, Wang Z, Cheng EH, Hsieh JJ.

Cell Rep. 2017 Mar 21;18(12):2893-2906. doi: 10.1016/j.celrep.2017.02.074.

43.

The ErbB3 receptor tyrosine kinase negatively regulates Paneth cells by PI3K-dependent suppression of Atoh1.

Almohazey D, Lo YH, Vossler CV, Simmons AJ, Hsieh JJ, Bucar EB, Schumacher MA, Hamilton KE, Lau KS, Shroyer NF, Frey MR.

Cell Death Differ. 2017 May;24(5):855-865. doi: 10.1038/cdd.2017.27. Epub 2017 Mar 17.

44.

Renal cell carcinoma.

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V.

Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. Review.

45.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

46.

ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation.

Schumacher MA, Hedl M, Abraham C, Bernard JK, Lozano PR, Hsieh JJ, Almohazey D, Bucar EB, Punit S, Dempsey PJ, Frey MR.

Cell Death Dis. 2017 Feb 23;8(2):e2622. doi: 10.1038/cddis.2017.42.

47.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

49.

The panoramic view of clear cell renal cell carcinoma metabolism: values of integrated global cancer metabolomics.

Hsieh JJ, Cheng EH.

Transl Androl Urol. 2016 Dec;5(6):984-986. doi: 10.21037/tau.2016.11.03. No abstract available.

50.

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.

Br J Dermatol. 2017 Jun;176(6):1649-1652. doi: 10.1111/bjd.15237. Epub 2017 Apr 24.

Supplemental Content

Loading ...
Support Center